Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04781699
Other study ID # ER22491844
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 19, 2021
Est. completion date September 1, 2022

Study information

Verified date November 2021
Source Sheffield Hallam University
Contact Simon Nichols, PhD
Phone 01142254327
Email s.j.nichols@shu.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary aim of this research is to explore the adherence and drop-out from early cardiac rehabilitation (CR), to inform interventions to support patient's adherence to CR and facilitate maintenance. The secondary aim is to understand which aspects of CR are essential for improving health-related quality of life in the short and long-term. This research will comprise four stages adopting a mixed-methods, quasi-experimental, repeated measures design.


Description:

This study will explore the attitudes of patients and healthcare practitioners towards the components of CR (diet, smoking, and medication) and their relationship with improving patients' perceived health and wellbeing. We will apply user-centred approaches by working with patients and other stakeholders to develop the best solutions that help patients to adhere to relevant health behaviour changes. The proposed study will use a mix of surveys and interviews. This will conclude with a two-day workshop with patients and health care professionals to come up with recommendations for improving adherence to CR. Stage 1: A bespoke survey has been designed to examine the perceptions of patients and health care professionals. The survey will include questions around, CR referral, uptake and adherence rates. Factors that hinder and improve attendance to CR will be explored. Surveys will be distributed amongst CR patients across six centres in the United Kingdom: Sheffield, London, North of England, Scotland, Wales, and Northern Ireland. The aim is to collect survey responses from 498 patients. Stage 2: Qualitative interviews will be carried out with both patients and professionals. Topics will include factors that improve or hinder attendance and completion of CR. In addition, factors in CR which assist with improving quality of life will be explored. This will provide a more in-depth understanding of challenges to attendance identified in study 1. Up to 10 patients from each site will be interviewed, plus up to 20 health care professionals across all sites. Stage 3: Up to 30 participants recruited across regions will be invited to take part in a two-day workshop. The two-day co-design workshop will involve patients, clinicians, CR providers, and researchers. The aim is to develop recommendations and approaches to improving attendance and completion of CR. This will include improvements to existing CR. Study Conduct, Participant identification, inclusion, and exclusion Each of the six sites currently delivers comprehensive early CR and provides access to patients and providers with lived experience of the core components and behaviour changes associated with CR adherence. A local principal investigator who is responsible for the leadership of a research study has been identified at each site to oversee conduct of the study protocol and facilitate participant recruitment. Participants will represent a range of demographic backgrounds including ethnicity, socioeconomic group, cardiac diagnosis and length of engagement with CR. Recruitment to interviews will stop when no new themes are being identified from the interviews (data saturation). Healthcare professionals meeting our inclusion criteria will be approached directly, by the principal investigator at each study site. People interested in the study will be given an information sheet, and a minimum of 24 hours to consider study information before recruitment. Patients will be identified and invited to take part in the qualitative study by their healthcare professional upon referral to a CR programme. Patients providing verbal consent will then be contacted by a member of the research team. These patients will also be invited to take part in the qualitative interviews investigating long-term adherence to CR (after six months). In the event that too few of the patients are available for the interview after six months, further patients will be retrospectively identified through the patient records kept by the CR team. Participant consent and withdrawal Written informed consent will be sought from participants at all stages of the study including the initial survey, subsequent interviews and/or co-design event. It will be clear at all times throughout the research that participation is voluntary and withdrawal at any stage without challenge will be supported. Information relating to participant consent will make explicit than any data collected prior to the participants' withdrawal may be retained for analysis. Survey Surveys will be completed online or sent via post to all identified eligible patients. If a patient decides to complete the survey online, an accessible email link will be sent via a web link using a licensed copy of Qualtrics survey software. Participants will be asked to read the study information and sign/digitally tick consent before proceeding to the survey questions. Interviews and co-design event Eligible participants who are interested in our study will be provided with written information sheets and offered the opportunity to ask questions by phone, email or where possible, face-to-face with the local principal investigator and/or a member of the core research team at Sheffield Hallam University. Participants will be given a minimum of 24 hours to consider the study information, after which time they will be contacted to arrange attendance. Ethical considerations Risks to participants are estimated to be low; although it is possible there may be some emotional effect of discussing issues and experiences related to cardiovascular disease, treatment, and its potential impact on quality of life. Participants will be made aware of the nature of the topics to be discussed during the informed consent process so that they know what to expect. Participants will be made aware that they can withdraw from the study at any time, or avoid any topics that cause discomfort. The co-design workshop will be facilitated in a way that fosters sharing, non-judgment, and equality amongst group members. It is important to manage expectations that group discussions during workshops are for research purposes, and not directly intended as patient support groups. Links and contact details will be provided for patients who express a need for further support, both verbally and via participant information sheets.


Recruitment information / eligibility

Status Recruiting
Enrollment 498
Est. completion date September 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria patients: - Patients who fall within the National Audit of CR (NACR) priority groups. These include Myocardial Infarction (MI), MI + Percutaneous Coronary Intervention (PCI), PCI, Coronary Artery Bypass Graft (CAGB), and Heart Failure. - Aged over 18 years (i.e., all adults). - No evidence of cognitive impairment which will limit the ability to follow basic instructions. Inclusion criteria professionals: - Those who have a key responsibility for delivering or managing CR at one of the six local sites, including - healthcare professionals and/or CR providers. Exclusion criteria patients: - Patients who fall outside of the NACR priority groups. - Aged under 18 years (i.e., all adults). - Evidence of cognitive impairment which will limit the ability to follow basic instructions (Participants unable to give informed consent). Exclusion criteria professionals: - Trainee or administrative staff members. - Staff members with less than four months of experience working in CR.

Study Design


Locations

Country Name City State
United Kingdom Belfast Health and Social Care Trust Belfast
United Kingdom NHS Ayrshire and Arran Kilmarnock
United Kingdom Royal Brompton Hospital London Harefield Middlesex
United Kingdom Northumbria Healthcare NHS Foundation Trust Newcastle Upon Tyne Blyth
United Kingdom Sheffield Teaching Hospitals Sheffield South Yorkshire
United Kingdom Aneurin Bevan University Health Board Ystrad Mynach Gwent

Sponsors (8)

Lead Sponsor Collaborator
Sheffield Hallam University Aneurin Bevan University Health Board, AstraZeneca, Belfast Health and Social Care Trust, NHS Ayrshire and Arran, Northumbria Healthcare NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Intervention development Via a co-design event with patients and healthcare professionals to create a clear description of an intervention package. This is based on factors reported from the primary and secondary outcome measures. 10 months after study start date
Primary Reasons people attend early cardiac rehabilitation (quantitative method). Using a pre-developed questionnaire. Start of cardiac rehabilitation
Primary Attendance to early cardiac rehabilitation Measured by number of patients referred to cardiac rehabilitation and proportion who take up cardiac rehabilitation. End of cardiac rehabilitation ~ 8 weeks.
Primary Reasons people adhere to early cardiac rehabilitation (quantitative method). Using a pre-developed questionnaire. End of cardiac rehabilitation ~ 8 weeks
Primary Reasons people adhere to cardiac rehabilitation (qualitative method). Using a semi-structured qualitative interview. End of cardiac rehabilitation ~ 8 weeks
Primary Reasons people adhere to core components of cardiac rehabilitation (quantitative method). Using a pre-developed questionnaire. 6 months after completion of cardiac rehabilitation
Primary Reasons people adhere to components of cardiac rehabilitation in the long term (qualitative method). Using a semi-structured qualitative interview. 6 months after completion of cardiac rehabilitation
Primary Reasons people drop-out of cardiac rehabilitation (quantitative method). Using a pre-developed questionnaire. End of cardiac rehabilitation ~ 8 weeks
Primary Reasons people drop-out of cardiac rehabilitation (quantitative method). Using a pre-developed questionnaire. 6 months after completion of cardiac rehabilitation
Primary Drop-out of early cardiac rehabilitation (quantitative method) Drop-out will be defined as attending less than 50% of sessions. End of cardiac rehabilitation ~ 8 weeks.
Primary Reasons people drop-out of early cardiac rehabilitation (qualitative method) Using a semi-structured qualitative interview. End of cardiac rehabilitation ~ 8 weeks.
Secondary Patient perceptions on which components of cardiac rehabilitation improve health related quality of life (quantitative method). Using a pre-developed questionnaire. Start of cardiac rehabilitation
Secondary Patient perceptions on which components of cardiac rehabilitation improve health related quality of life (quantitative method). Using a pre-developed questionnaire. End of cardiac rehabilitation ~ 8 weeks
Secondary Patient perceptions on which components of cardiac rehabilitation improve health related quality of life (quantitative method). Using a pre-developed questionnaire. 6 months after completion of cardiac rehabilitation
Secondary Patient perceptions on which components of cardiac rehabilitation improve health related quality of life (qualitative method). Using a semi-structured qualitative interview. End of cardiac rehabilitation ~ 8 weeks
Secondary Patient perceptions on which components of cardiac rehabilitation improve health related quality of life (qualitative method). Using a semi-structured qualitative interview. 6 months after completion of cardiac rehabilitation
Secondary Professional perspectives of supporting adherence to core components of cardiac rehabilitation (qualitative method). Using a semi-structured qualitative interview. Within 5 months from study start date.
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A